May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Intraocular Penetration of Oral Linezolid in Humans
Author Affiliations & Notes
  • R.G. Fiscella
    Pharmacy/Ophthalmology, Univ of Illinois at Chicago, Chicago, IL, United States
  • M. Khan
    Ophthalmology, Univ of Illinois at Chicago, Chicago, IL, United States
  • W.W. Lai
    Ophthalmology, Univ of Illinois at Chicago, Chicago, IL, United States
  • H. Becker
    Ophthalmology, Univ of Illinois at Chicago, Chicago, IL, United States
  • S. Labib
    Pharmacy, Univ of Illinois at Chicago, Chicago, IL, United States
  • J. Pulido
    Pharmacy, Univ of Illinois at Chicago, Chicago, IL, United States
  • B. Buerk
    Pharmacy, Univ of Illinois at Chicago, Chicago, IL, United States
  • N. Blair
    Pharmacy, Univ of Illinois at Chicago, Chicago, IL, United States
  • M. Shapiro
    Pharmacy, Univ of Illinois at Chicago, Chicago, IL, United States
  • Footnotes
    Commercial Relationships  R.G. Fiscella, Pharmacia F; M. Khan, None; W.W. Lai, None; H. Becker, None; S. Labib, None; J. Pulido, None; B. Buerk, None; N. Blair, None; M. Shapiro, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4424. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.G. Fiscella, M. Khan, W.W. Lai, H. Becker, S. Labib, J. Pulido, B. Buerk, N. Blair, M. Shapiro; Intraocular Penetration of Oral Linezolid in Humans . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4424.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Linezolid is a synthetic antibiotic of the oxazolidinone class. It has inhibitory activity against gram-positive bacteria including methicillin resistant Staphylococcus aureus, vancomycin resistant enterococci (VRE), and penicillin resistant Streptococcus pneumoniae. Linezolid also exhibits activity against some anaerobes including Propionbacterium acnes, Peptostreptococcus spp. Bacteroides fragilis, C. difficile, and C. perfringens. We wished to study if the oral 600mg tablet could produce inhibitory levels in the aqueous and vitreous humor after one or two tablets.Methods: Patients 18 years of age or older undergoing primary vitrectomy surgery were given either one tablet or 2 tablets (12 hours apart) anywhere from 1 to 4 hours prior to surgery. Prior to any surgical procedure, aqueous, vitreous and blood samples were obtained from the patient. The aqueous and vitreous samples were placed on ice and then frozen. The blood was centrifuged and the serum collected and frozen for future analysis along with the aqueous and vitreous.Results:13 patients receiving 1 tablet of linezolid had aqueous and vitreous fluids were sampled less than 2 hours after administration. Aqueous, vitreous and serum averaged 0.77 + 0.6 mcg/ml, 0.3+ 0.3mcg/ml and 5.0+ 3.25 mcg/ml respectively. 9 patients had aqueous, vitreous and serum samples obtained more than 2 hours (mean 214 minutes + 64) after one tablet administration with resulting concentrations of 3.8 + 1.2, 2.31 + 1.4 and 7.6 + 2.7 mcg/ml, respectively. 7 patients were administered 2 tablets, 12 hours apart (sample obtained mean time of 351 + 232 minutes) and obtained aqueous, vitreous, and serum concentrations of 6.6 + 2.7mcg/ml, 5.7 + 2.7 mcg/ml and 10.3 + 4.1mcg/ml. Ocular fluids exhibited mean inhibitory levels against all gram-positive bacteria including VRE, MRSA and Streptococcus pneumoniae. Conclusions: Oral linezolid 600mg q 12 hours x 2 doses provided mean inhibitory levels in the aqueous and vitreous fluids against major gram-positive bacteria including VRE, MRSA and Streptococcal species.

Keywords: antibiotics/antifungals/antiparasitics • endophthalmitis • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×